Effect of secretin and cholecystokinin-pancreozymin on plasma CEA concentration in patients with pancreatic carcinoma and pancreatitis.
Plasma CEA concentration before and after administration of secretin and cholecystokinin-pancreozymin has been determined in 89 patients with neoplastic or inflammatory pancreatric disease and other neoplastic and nonneoplastic disorders. The purpose of the study was to expore the specificity and sensitivity of such a provocation tests. Some rise of the plasma CEA concentration after hormonal stimulation could be observed in several patients in the various groups. However, none of the 37 patients with nonpancreatic disease who had a basal CEA concentration of 6 micrograms/l or less had a maximal CEA concentration above 13 micrograms/l after the stimulation whereas 7 out of 31 patients with pancreatic disease (3 with pancreatic carcinoma and 4 with chronic pancreatitis) showed such an elevation of plasma CEA concentration. Thus, the provocation test showed a satisfactory specificity for pancreatic disease but a low sensitivity. It is suggested that the possibility of an effect of physiologically released gastrointestinal hormones should be considered when "unexplained" high CEA values are found in plasma samples from nonfasting patients.
D000818:Animals; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D002766:Cholecystokinin; D005069:Evaluation Studies as Topic; D008297:Male; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000175:diagnosis*; D010195:Pancreatitis / Q000097:blood / Q000175:diagnosis*; D012633:Secretin
D002272:Carcinoembryonic Antigen; D012633:Secretin; D002766:Cholecystokinin